Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults – ClinicalTrials.gov

Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Actual Study Start Date :	August 28, 2020
Actual Primary Completion Date :	March 5, 2021
Estimated Study Completion Date :	February 14, 2023

Info This site is a curated archive of articles with a link to the source. Keywords and topics covered in the publication can be found above. Click on the tag to view a listing of similar articles.
Links Are any links broken? The page may have been taken down. Visit archive.is or archive.org to view the archive snapshot.
Links Help fight censorship and preserve information on the internet. Archive this source and links on archive.is and archive.org. Save a local copy on your own hard drive.